{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:40:07Z","timestamp":1792482007739,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01620-w","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:08:00Z","timestamp":1792480080000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Therapy for Gastric Adenocarcinoma with Signet Ring Cells: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7335-8319","authenticated-orcid":false,"given":"Evgenia","family":"Mela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximos","family":"Frountzas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fani","family":"Apostolidou Kiouti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriani","family":"Nikolakopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Bettina","family":"Haidich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Schizas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Triantafyllou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"1620_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70090","author":"H Sung","year":"2026","unstructured":"Sung H, Filho AM, Laversanne M, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin. 2026. https:\/\/doi.org\/10.3322\/caac.70090.","journal-title":"CA Cancer J Clin"},{"key":"1620_CR2","unstructured":"NIH USA National Cancer Institute."},{"key":"1620_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.7528","author":"D Marrelli","year":"2011","unstructured":"Marrelli D, Pedrazzani C, Morgagni P, et al. Changing clinical and pathological features of gastric cancer over time. Br J Surg. 2011. https:\/\/doi.org\/10.1002\/bjs.7528.","journal-title":"Br J Surg"},{"key":"1620_CR4","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-09-0250","author":"H Wu","year":"2009","unstructured":"Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomarkers Prev. 2009. https:\/\/doi.org\/10.1158\/1055-9965.EPI-09-0250.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1620_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/apm.1965.64.1.31","author":"P Lauren","year":"1965","unstructured":"Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histoclinical classification. Acta Pathol Microbiol Scand. 1965. https:\/\/doi.org\/10.1111\/apm.1965.64.1.31.","journal-title":"Acta Pathol Microbiol Scand"},{"key":"1620_CR6","doi-asserted-by":"publisher","DOI":"10.5858\/2004-128-765-DTITIA","author":"DE Henson","year":"2004","unstructured":"Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973\u20132000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004. https:\/\/doi.org\/10.5858\/2004-128-765-DTITIA.","journal-title":"Arch Pathol Lab Med"},{"key":"1620_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/his.13975","author":"IDN Nagtegaal","year":"2020","unstructured":"Nagtegaal IDN, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020. https:\/\/doi.org\/10.1111\/his.13975.","journal-title":"Histopathology"},{"key":"1620_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-018-0868-0","author":"C Mariette","year":"2019","unstructured":"Mariette C, Carneiro F, Grabsch HI, et al. Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma. Gastric Cancer. 2019. https:\/\/doi.org\/10.1007\/s10120-018-0868-0.","journal-title":"Gastric Cancer"},{"key":"1620_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.004","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004.","journal-title":"Ann Oncol"},{"key":"1620_CR10","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Gastric cancer. version 3.2025. Natl Compr Cancer Netw (2025). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf."},{"key":"1620_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32557-1","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019. https:\/\/doi.org\/10.1016\/S0140-6736(18)32557-1.","journal-title":"Lancet"},{"key":"1620_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26180","author":"N Homann","year":"2012","unstructured":"Homann N, Pauligk C, Luley K, et al. Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. Int J Cancer. 2012. https:\/\/doi.org\/10.1002\/ijc.26180.","journal-title":"Int J Cancer"},{"key":"1620_CR13","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-14690-y","author":"EC Gertsen","year":"2024","unstructured":"Gertsen EC, van der Veen A, Brenkman HJF, et al. Multimodal therapy versus primary surgery for gastric and gastroesophageal junction diffuse type carcinoma, with a focus on signet ring cell carcinoma: a nationwide study. Ann Surg Oncol. 2024. https:\/\/doi.org\/10.1245\/s10434-023-14690-y.","journal-title":"Ann Surg Oncol"},{"key":"1620_CR14","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6541-3","author":"U Heger","year":"2018","unstructured":"Heger U, Sisic L, Nienh\u00fcser H, et al. Neoadjuvant therapy improves outcomes in locally advanced signet-ring-cell containing esophagogastric adenocarcinomas. Ann Surg Oncol. 2018. https:\/\/doi.org\/10.1245\/s10434-018-6541-3.","journal-title":"Ann Surg Oncol"},{"key":"1620_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3182352647","author":"M Messager","year":"2011","unstructured":"Messager M, Lefevre JH, Pichot-Delahaye V, et al. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Ann Surg. 2011. https:\/\/doi.org\/10.1097\/SLA.0b013e3182352647.","journal-title":"Ann Surg"},{"key":"1620_CR16","unstructured":"Centre for Reviews and Dissemination. PROSPERO: International prospective register of systematic reviews. Univ York. https:\/\/www.crd.york.ac.uk\/prospero\/."},{"key":"1620_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1620_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.01.021","author":"J McGowan","year":"2016","unstructured":"McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.01.021.","journal-title":"J Clin Epidemiol"},{"key":"1620_CR19","unstructured":"Cochrane Effective Practice and Organisation of Care (EPOC). Data collection form. EPOC resources for review authors (2017). https:\/\/epoc.cochrane.org\/resources\/epoc-specific-resources-review-authors."},{"key":"1620_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"1620_CR21","unstructured":"Sterne JAC, Higgins JPT, ROBINS-I V2. : Risk of bias in non-randomized studies of interventions. Version 2. riskofbias.info (2024). https:\/\/www.riskofbias.info\/welcome\/robins-i-v2."},{"key":"1620_CR22","unstructured":"Rohatgi A. WebPlotDigitizer. Version 5.2. Automeris LLC; 2024. https:\/\/automeris.io\/WebPlotDigitizer."},{"key":"1620_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01308-8","author":"N Liu","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021. https:\/\/doi.org\/10.1186\/s12874-021-01308-8.","journal-title":"BMC Med Res Methodol"},{"key":"1620_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","author":"MK Parmar","year":"1998","unstructured":"Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998. https:\/\/doi.org\/10.1002\/(SICI)1097-0258(19981230)17:24%3C2815::AID-SIM110%3E3.0.CO;2-8.","journal-title":"Stat Med"},{"key":"1620_CR25","unstructured":"Higgins JPT, Thomas J, Chandler J, et al. editors. Cochrane handbook for systematic reviews of interventions. Version 6.5. Cochrane (2024). https:\/\/www.cochrane.org\/handbook."},{"key":"1620_CR26","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing; 2024. https:\/\/www.r-project.org\/."},{"key":"1620_CR27","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i03","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010. https:\/\/doi.org\/10.18637\/jss.v036.i03.","journal-title":"J Stat Softw"},{"key":"1620_CR28","unstructured":"Viechtbauer W. metadat: Meta-analysis datasets. R package version 1.0\u20130 (2024). https:\/\/CRAN.R-project.org\/package\/metadat."},{"key":"1620_CR29","unstructured":"Bates D, Maechler M, Jagan M et al. Matrix: Sparse and dense matrix classes and methods. R package version 1.9-8 (2024). https:\/\/CRAN.R-project.org\/package\/Matrix."},{"key":"1620_CR30","unstructured":"Gilbert P, Varadhan R, numDeriv. Accurate numerical derivatives. R package version 2016.8\u20131.1 (2024). https:\/\/CRAN.R-project.org\/package\/numDeriv."},{"key":"1620_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-020-01136-7","author":"Y Iwasaki","year":"2021","unstructured":"Iwasaki Y, Terashima M, Mizusawa J, et al. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. Gastric Cancer. 2021. https:\/\/doi.org\/10.1007\/s10120-020-01136-7.","journal-title":"Gastric Cancer"},{"key":"1620_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-023-03114-w","author":"Y Ma","year":"2023","unstructured":"Ma Y, Wang Y, Hu C, et al. The percentages of signet-ring cells (SRCs) affects the prognosis after radical gastrectomy for advanced gastric cancer. Langenbecks Arch Surg. 2023. https:\/\/doi.org\/10.1007\/s00423-023-03114-w.","journal-title":"Langenbecks Arch Surg"},{"key":"1620_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152419","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Wang P, Tian Y. The impact of neoadjuvant chemotherapy on survival outcomes in gastric signet-ring cell carcinoma: an international multicenter study. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17152419.","journal-title":"Cancers (Basel)"},{"key":"1620_CR34","unstructured":"Hamilton S, Aaltonen L. World Health Organization classification of tumours: pathology and genetics of tumours of the digestive system. IARC; 2000."},{"key":"1620_CR35","doi-asserted-by":"publisher","DOI":"10.1615\/critrevoncog.v14.i2-3.30","author":"N Jonckheere","year":"2008","unstructured":"Jonckheere N, Van Seuningen I. The membrane-bound mucins: how large O-glycoproteins play key roles in epithelial cancers and hold promise as biological tools for gene-based and immunotherapies. Crit Rev Oncog. 2008. https:\/\/doi.org\/10.1615\/critrevoncog.v14.i2-3.30.","journal-title":"Crit Rev Oncog"},{"key":"1620_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-014-0110-9","author":"B Hultman","year":"2014","unstructured":"Hultman B, Mahteme H, Sundbom M, Ljungman M, Larsson R, Nygren P. Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy. J Exp Clin Cancer Res. 2014. https:\/\/doi.org\/10.1186\/s13046-014-0110-9.","journal-title":"J Exp Clin Cancer Res"},{"key":"1620_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0133-7","author":"S Pernot","year":"2018","unstructured":"Pernot S, Dubreuil O, Aparicio T, et al. Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study. Br J Cancer. 2018. https:\/\/doi.org\/10.1038\/s41416-018-0133-7.","journal-title":"Br J Cancer"},{"key":"1620_CR38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055531","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al. MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006. https:\/\/doi.org\/10.1056\/NEJMoa055531.","journal-title":"N Engl J Med"},{"key":"1620_CR39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503701","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2503701.","journal-title":"N Engl J Med"},{"key":"1620_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2021.09.003","author":"F Roviello","year":"2022","unstructured":"Roviello F, Marano L, Ambrosio MR, et al. Signet ring cell percentage in poorly cohesive gastric cancer patients: a potential novel predictor of survival. Eur J Surg Oncol. 2022. https:\/\/doi.org\/10.1016\/j.ejso.2021.09.003.","journal-title":"Eur J Surg Oncol"},{"key":"1620_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-022-01331-8","author":"Japanese Gastric Cancer Association","year":"2023","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer. 2023. https:\/\/doi.org\/10.1007\/s10120-022-01331-8.","journal-title":"Gastric Cancer"},{"key":"1620_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-281","author":"G Piessen","year":"2013","unstructured":"Piessen G, Messager M, Le Malicot K, et al. Phase II\/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas - PRODIGE 19 - FFCD1103 - ADCI002. BMC Cancer. 2013. https:\/\/doi.org\/10.1186\/1471-2407-13-281.","journal-title":"BMC Cancer"},{"key":"1620_CR43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4019","author":"C Eveno","year":"2019","unstructured":"Eveno C, Adenis A, Bouche O, et al. Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: a multicenter, randomized phase II study (PRODIGE 19). J Clin Oncol. 2019. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.4019.","journal-title":"J Clin Oncol"},{"key":"1620_CR44","doi-asserted-by":"crossref","unstructured":"Tabernero J, Al-Batran SE, Wainberg ZA et al. LBA81 \u2013 Final overall survival (OS) and the association of pathological outcomes with event-free survival (EFS) in MATTERHORN: a randomized, phase III study of durvalumab (D) plus FLOT in resectable gastric\/gastroesophageal junction adenocarcinoma. Presented ESMO Congress 2025. https:\/\/cslide.ctimeetingtech.com\/esmo20.","DOI":"10.1016\/j.annonc.2025.09.096"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01620-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01620-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01620-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:08:06Z","timestamp":1792480086000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01620-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1620"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01620-w","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"4 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"240"}}